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To study the role of single agent carboplatin chemotherapy in patients with metastatic seminoma based on the data from two
randomised trials. In subgroup analyses in patients with different disease characteristics, the outcome treated with either single agent
carboplatin or cisplatin-based combination chemotherapy was compared. Individual patient data from two randomised European
trials involving patients with metastatic seminoma were gathered. The primary endpoint for all analyses was progression-free survival.
The source data of 361 patients, 184 treated with cisplatin-based combinations and 177 treated with carboplatin single agent therapy,
were entered into the analysis. Patient characteristics were comparable among the cisplatin-based and the carboplatin single agent
treated patient groups with lymph nodes and lungs being the most frequent metastatic sites in 92 and 8% of patients, respectively.
Overall, patients treated with single agent carboplatin had an inferior 5-year overall (89 and 94%; P¼0.09) and progression-free
survival rate (72 and 92%; Po 0.0001) compared with patients receiving cisplatin-based combinations. For all investigated subgroups
(based on age, prior radiation therapy, metastatic sites), carboplatin single agent therapy was found to be inferior to cisplatin-based
combination chemotherapy. In conclusion, carboplatin single agent therapy cannot be recommended as standard treatment for any
patient subgroup with advanced metastatic seminoma and cisplatin-based combination regimens remain the standard of care.
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Today, approximately 70–80% of patient with testicular metastatic
germ cell cancer can be cured with standard-dose cisplatin-based
combination chemotherapy (Einhorn, 1990; Bosl and Motzer,
1997). With long-term cure rates of 80–95%, patients with
metastatic seminoma seem to exhibit an even better prognosis
than patients with nonseminomatous germ cell cancer (Mead and
for the International Germ Cell Cancer Collaborative Group, 1997).
This is also reflected by the fact that the International Germ Cell
Cancer Cooperative Group (IGCCCG) classification does not
categorise patients with pure seminoma into the ‘poor prognosis’
group (Mead and for the International Germ Cell Cancer
Collaborative Group, 1997). Three and four cycles of bleomycin,
etoposide, and cisplatin (BEP) are considered the standard
treatment for patients with metastatic seminoma within the good
and intermediate prognosis criteria IGCCCG group, respectively
(Mead and for the International Germ Cell Cancer Collaborative
Group, 1997). However, since most patients with seminoma are
diagnosed at stage I and widespread metastatic disease is rare, only
a few studies regarding the optimal treatment of patients with
metastatic seminoma have been performed. Due to the exception-
ally high cure rate of patients with advanced seminoma, the
reduction of treatment-related toxicity, while at the same time
maintaining efficacy, has been the focus of investigations in the
past years. Cisplatin-based combination chemotherapy was
reported to cause significant acute and long-term side effects in
the population of seminoma patients, who are usually about 10–15
years older than patients with nonseminomatous disease. Since
cisplatin was reported to have a high single agent activity in
seminoma and due to the availability of the cisplatin analogue
carboplatin with an improved toxicity profile as compared to its
parent compound, phase II studies have investigated single agent
carboplatin therapy in patients with metastatic seminoma (Oliver
et al, 1990; Horwich et al, 1992; Schmoll et al, 1993). Horwich et al
(1992) reported an excellent 3-year overall survival rate of 91% for
single agent carboplatin in 70 patients with metastatic seminoma.
Similar results were reported by Schmoll et al (1993) and Oliver
et al (1990). Therapy-associated toxicities were very moderate in
all three studies.
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trials, one in Great Britain and one in Germany comparing
carboplatin single agent therapy with cisplatin-based combina-
tions. In the British trial single agent carboplatin was compared
with the combination of cisplatin and etoposide whereas in the
German study the combination of cisplatin, etoposide and
ifosfamide was chosen as the standard arm. The British seminoma
study was closed early after the enrollment of 130 patients due to
poor accrual and to results of randomised trials demonstrating
inferiority of carboplatin-based combinations compared with
cisplatin-based regimens in patients with metastatic nonseminoma
(Bokemeyer et al, 1996; Horwich et al, 2000). The final results of
the German randomised seminoma trial on single agent carbopla-
tin have not yet been fully published; however, the first analysis
after completion of accrual has indicated an inferiority of
carboplatin single agent therapy regarding progression-free
survival (Clemm et al, 2000). Neither the British nor the German
study had included enough patients to answer two important
questions in advanced seminoma patients: First, are there any
subgroups among patients with metastatic seminoma, which may
still achieve an equally good outcome with carboplatin single agent
therapy as with cisplatin-based combinations? Second, which
pretreatment factors predict the chances of survival after
chemotherapy for metastatic seminoma? We have therefore
combined the individual patient data from both European
randomised trials in this analysis in order to search for possible
patient subgroups with equivalent outcome after either carboplatin
single agent therapy or cisplatin combination therapy.
PATIENTS AND METHODS
The individual patient data of 130 patients with advanced
seminoma included in the British trial and of 250 patients included
in the German randomised phase III trial were obtained (Clemm
et al, 2000; Horwich et al, 2000). In total, 19 patients were excluded
from the analysis due to missing data. All patients had been treated
with either four to six cycles of carboplatin single agent therapy or
four cycles of cisplatin-based combination chemotherapy either at
initial diagnosis or at relapse after radiotherapy for stages I or IIA/
B disease. Within the German randomised trial, patients received
four to six cycles of carboplatin at a dose of 400mgm
 2 (actual
dose corrected according to creatinine clearance) given on day 1 of
a 4-week cycle or 4 cycles of the VIP regimen consisting of
etoposide 100mgm
 2, ifosfamide 1200mgm
 2 and cisplatin
20mgm
 2, all administered days 1 through 5 of a 4-week cycle.
This study recruited patients from July 1990 through August 1999.
The VIP regimen was chosen as the standard arm in the German
randomised trial since VIP had shown a high complete remission
rate, no pulmonary toxicity and a very low relapse rate in a
preceding phase II trial in patients with seminoma (Clemm et al,
1993).
Patients in the British randomised study were treated with four
cycles of carboplatin 400mgm
 2 (actual dose corrected according
to creatinine clearance) given on day 1 or with the combination of
etoposide 120mgm
 2 days 1–3 and cisplatin 20mgm
 2 days 1–5.
Both regimens were given in 3-week intervals. The British trial
started in 1990 and was closed early after 130 patients had been
randomised following the recommendation of the independent
data monitoring committee. Inclusion criteria were almost
identical for both trials. Advanced disease was defined as the
presence of abdominal lymph node metastases 45cm, supra-
diaphragmatic lymph nodes or visceral metastases. High-dose
chemotherapy with peripheral stem cell support was not used as
first-line therapy in any of these patients.
The individual patient data were pooled and included in a SAS
data bank (version 8.8; SAS Institute Inc., Cary, NC, USA). A total
of 19 patients in whom only an incomplete data set with more than
two missing variables was obtained were excluded from further
analysis.
Progression-free and overall survival were calculated from the
date of randomisation until the date of relapse and the date of
death, respectively. Patients were analysed according to the ‘intent-
to-treat’ principle.
The primary end point for subgroup analyses was progression-
free survival, which was calculated from the date of randomisation
to the date of disease progression. Survival rates as well as median
follow-up were calculated using the Kaplan–Meier method.
Comparisons in survival were carried out using the Log-Rank test
(Kaplan and Meier, 1958; Cox and Oakes, 1984). The following
subgroups were investigated: patients with lung metastases
(n¼29); without lung metastases (n¼332); with lymph node
metastases only (n¼263); without lymph node metastases
(n¼98); with nonpulmonary visceral metastases (n¼20); without
nonpulmonary visceral metastases (n¼341); patients with relapse
after prior radiation for stage I and IIA/B disease (n¼51); without
prior radiation (n¼310); patients younger than 30 years of age
(n¼59); patients between 30 and 50 years of age (n¼221);
patients older than 50 years of age (n¼56) (age missing in 25
patients).
Data are presented with two-tailed P-values (unadjusted for
multiple comparisons) and 95% confidence intervals for the
hazard ratios. Computations were performed using SAS-PC for
windows (version 8.0; SAS Institute Inc., Cary, NC, USA).
RESULTS
A total of 361 patients with complete data from both randomised
trials were entered into the pooled analysis.
In the German trial a progression-free and overall survival rate
of 72% [95% CI: 63–80%] and 90% [95% CI: 85–96%],
respectively, for the carboplatin treated patients and of 95%
[95% CI: 91–99%] and 95% [95% CI: 91–98%], respectively, for
the cisplatin group was reported after a median follow-up of 52
months [2–112 months]. Similar results have been achieved by the
British study with a progression-free and overall survival rate of
72% [95% CI: 60–83%] and 87% [95% CI: 78–96%] for the
carboplatin patients and of 85% [95% CI: 76–94%] and 91% [95%
CI: 83–98%] for the patients receiving cisplatin-based combina-
tions. Median follow-up in the British trial was 54 [2–112] months.
After pooling the individual patient data from both trials, a total
of 177 (49%) patients were treated with carboplatin single agent
therapy and 184 (51%) patients with cisplatin-based combinations.
Patient characteristics were well balanced between both groups
(Table 1). Of these 361 patients, 14% had relapsed after previous
radiation therapy. Median ages were 37 [range: 15–64 years] and
39 years [range: 21–71 years] for patients treated with carboplatin
and cisplatin-based therapy, respectively. Most patients had
gonadal primary tumours. Nonpulmonary visceral metastases
were present in 10 patients of each group, pulmonary metastases
in 11 patients of the carboplatin group, and 18 patients of the
cisplatin group. Lymph node metastases were the most common
metastatic sites in both groups (161 and 169 patients in the
carboplatin and cisplatin-based treated group, respectively).
In total, 90% of all patients belonged to the IGCCCG ‘good
prognosis’ group and 10% to the ‘intermediate prognosis’ group.
The median follow-up for all 361 patients was 4.5 years (range:
0.2–9 years) being virtually identical for both patient groups (4.6
years for the carboplatin group and 4.5 years for the cisplatin
group).
Haematological as well as non-haematological side effects were
significantly more frequent in the cisplatin-based combination
group than in the carboplatin treated patients (Table 2). Neither
neurotoxicity nor ototoxicity exceeded WHO grade 2.
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carboplatin treated patients whereas only 17 (9% [95% CI: 5–
13%]) relapses were observed following treatment with cisplatin-
based regimens (Po0.05). This resulted in an inferior 2-year
progression-free survival rate for carboplatin single agent therapy
as compared to cisplatin-based combinations with 72% [95% CI:
65–79%] vs 92% [95% CI: 87–96 %] (Po 0.001) (Figure 1). After a
median follow-up of approximately 4.5 years for both groups, 36
patients had died, 22 (12% [95% CI: 7-17%]) in the carboplatin,
and 14 (8% [95% CI: 4–12%]) in the cisplatin group, which
resulted in a nonsignificant difference of 5% in overall survival in
favour of cisplatin-based combinations (2-year overall survival
90% [95% CI: 85–95%] for carboplatin treated patients vs 94%
[95% CI: 91–98 %] for patients receiving cisplatin-based
combinations; P¼0.09) (Figure 2). Four patients died during
treatment with cisplatin-based combination chemotherapy, three
in the VIP group, and one in the EP group, whereas only one
patient died from carboplatin treatment.
For all the investigated subgroups the progression-free survival
rates achieved with cisplatin-based combination therapy were
superior to those following treatment with carboplatin single agent
therapy. Table 3 shows the relative increase in risk expressed as
hazard ratios for progression-free survival for patients receiving
carboplatin single agent therapy compared to cisplatin-based
combinations.
DISCUSSION
Due to the favourable toxicity profile, carboplatin single agent
therapy as well as carboplatin-based combination regimens have
been investigated in germ cell cancer patients within a number of
phase II and phase III trials (Bajorin et al, 1993; Schmoll et al,
1993; Bokemeyer et al, 1996; Horwich et al, 1997). The promising
results observed in phase II studies for single agent carboplatin
therapy in patients with metastatic seminoma have served as the
rationale for two randomised phase III trials conducted in Great
Britain and Germany, which compared single agent carboplatin
therapy with cisplatin-based combination regimens (Clemm et al,
2000; Horwich et al, 2000). The British trial, however, was
prematurely closed due poor accrual and to reports of inferiority
of carboplatin-based therapy in patients with metastatic non-
seminoma. The analysis of the 130 seminoma patients randomised
until closure of the trial revealed a nonsignificant 10% difference in
progression-free and a nonsignificant 5% difference in overall
survival in favour of the combination of cisplatin/etoposide
(Horwich et al, 2000). The results of the German randomised trial
based on 250 patients have demonstrated a statistically significant
21% absolute lower progression-free survival rate following
carboplatin therapy compared with the combination of cisplatin,
etoposide, and ifosfamide (Clemm et al, 2000). The overall survival
rate achieved with carboplatin single agent therapy was 8% lower
than that achieved with cisplatin-based regimens, but this was not
of statistically significant difference. The relatively small difference
in overall survival indicates that a large portion of patients failing
carboplatin single agent therapy can still achieve long-term cure
Table 1 Patient characteristics and treatment results
Carboplatin
(n¼177)
Cisplatin
(n¼184) Total (n¼361)
Median age (years) 37 [15–64] 39 [21–71] 38 [15–71]
Gonadal/
extragonadal
86%/14% 83%/17% 84%/16%
Prior radiation
therapy
No 85% 84% 84%
Yes 14% 14% 14%
No data 1% 2% 2%
Metastatic sites
Lymph nodes 91% 92% 92%
Nonpul. visceral 6% 5% 6%
Pulmonary 6% 10% 8%
IGCCCG stage at
diagnosis
Good 94% 95% 94%
Intermediate 6% 5% 6%
Response to
treatment
CR/PR 91% 95% 93%
SD/PD 9% 5% 7%
Relapse
Yes 29% 9% 19%
Salvage therapy n¼52 n¼17
SD-CTx 77% 59% 72%
HD-CTx 0% 6% 1%
Radiation 10% 24% 13%
No treatment 2% 0% 1%
No data 12% 12% 12%
Median follow-up
(years)
4.5 [0,3–9] 4.5 [0.2–9] 4.5 [0.2–9]
SD-CTx¼standard-dose chemotherapy; HD-CTx¼high-dose chemotherapy;
CR¼complete remission; PR¼partial remission; SD¼stable disease; PD¼
progressive disease.
Table 2 Maximum toxicity of carboplatin single agent therapy as compared to VIP or EP
British trial German trial
WHO Carboplatin (%) EP (%) Carboplatin (%) VIP (%)
Maximum haematological toxicity
Thrombocytopaenia Grade 1/2 35 6 12 14
Grade 3/4 9 8 6 27
Neutropaenia Grade 1/2 69 63 34 14
Grade 3/4 4 32 6 68
Maximum nonhaematological toxicity
Nausea/vomiting Grade 3/4 9 15 5 20
Diarrhoea Grade X 1 5 15 12 19
Neurotoxicity Grade X 1 0 11 2 14
Ototoxicity Grade X 10 1 5 3 3
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with salvage chemotherapy have also been reported for seminoma
patients failing first-line cisplatin-based chemotherapy (Fle ´chon
et al, 2001).
Based on the similar survival rates observed in both studies, we
have combined the individual patient data from both the British
and German randomised trials in order to definitively determine
the role of carboplatin in a large group of seminoma patients as
well as to investigate whether specific good prognostic patient
subgroups with an equivalent outcome following either carboplatin
single agent or cisplatin-based combination chemotherapy could
be identified.
The results of our analysis clearly confirm the inferiority of
carboplatin single agent treatment to cisplatin-based regimens
regarding progression-free survival. The overall survival rate is
also 5% lower following carboplatin therapy compared with
cisplatin-based combinations. Even with the 361 patients from
the two randomised trials, a clinically meaningful difference
of 5% in overall survival could not be demonstrated with statis-
tical significance, since this calculation would have needed
more than 600 patients. However, with the consistency of the
data reported in both trials, it is likely that a small but
true survival difference exists in favour of cisplatin-based
combinations.
* 2-year progression-free survival rates 
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Figure 1 Progression-free survival rates for patients from two randomised studies receiving either cisplatin-based combination chemotherapy or
carboplatin single agent therapy for metastatic seminoma (n¼361).
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Figure 2 Overall survival for patients from two randomised studies receiving either cisplatin-based combination chemotherapy or carboplatin single agent
therapy for metastatic seminoma (n¼361).
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regimens may achieve an efficacy similar to BEP or VIP. Favorable
results, comparable with the results achieved with carboplatin
monotherapy in phase II studies, have been reported in phase II
studies for the combination of carboplatin and cyclophosphamide
or ifosfamide, but these regimens have never been tested within
randomised phase III including only patients with advanced
seminoma. The only three randomised studies published thus far
comparing carboplatin with cisplatin-based combinations have
mainly included patients with metastatic nonseminoma and only a
small group of seminoma patients (Bajorin et al, 1993; Bokemeyer
et al, 1996; Horwich et al, 1997).
As expected, cisplatin-based combination regimens were
significantly more toxic than carboplatin single agent therapy.
However, cisplatin-related toxicity was acceptable and did not
outweigh the cisplatin-induced improvement in survival. Accord-
ing to the factors investigated by the IGCCCG study, we have
differentiated six subgroups in our randomised patient population
based on the presence of pulmonary metastases, presence of
nonpulmonary visceral metastases or presence of lymph node
metastases only in order to investigate the potential role of
carboplatin single agent therapy among these separate patient
cohorts with specific characteristics. However, no patient sub-
group could be identified for which carboplatin had achieved an
equivalent progression-free survival rate to cisplatin-based treat-
ment. Even in patients with lymph node metastases only, a
subgroup considered to exhibit a better prognosis than patients
with visceral metastases, cisplatin-based combination therapy
turned out to be significantly superior to carboplatin single agent
therapy.
In conclusion, single agent carboplatin cannot be recommended
as an equivalent therapeutic alternative to cisplatin-based combi-
nation therapy for patients with metastatic seminoma. Carboplatin
may only be considered in those few patients who are unable to
tolerate cisplatin-based regimens due to co-morbidities. Based on
the results of the present analysis, these patients can now be
exactly informed about their chances of cure and relapse rates
when choosing carboplatin single agent treatment.
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